MedPath

Valemetostat

Generic Name
Valemetostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H34ClN3O4
CAS Number
1809336-39-7
Unique Ingredient Identifier
60RD0234VE
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Phase 2
Not yet recruiting
Conditions
Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Interventions
Other: Genetic testing
Drug: Valemetostat Tosylate
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Procedure: Bone scan
Procedure: FDG-Positron Emission Tomography
Procedure: PSMA PET Scan
Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cabazitaxel
Drug: Abiraterone Acetate
Drug: Enzalutamide
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
First Posted Date
2024-10-09
Last Posted Date
2025-01-03
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
474
Registration Number
NCT06632977
Locations
🇺🇸

Helen F Graham Cancer Center, Newark, Delaware, United States

🇺🇸

Medical Oncology Hematology Consultants PA, Newark, Delaware, United States

🇺🇸

Mount Sinai Hospital, New York, New York, United States

and more 2 locations

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Phase 1
Not yet recruiting
Conditions
Squamous Non-small Cell Lung Cancer
Lung Cancer
Sinonasal Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Carcnimona
Interventions
Drug: pembrolizumab
Drug: valemetostat
First Posted Date
2023-05-30
Last Posted Date
2025-01-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
47
Registration Number
NCT05879484
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy